OxiGene cancer news

OxiGene will restructure and reduce headcount by 20 (49%) to 21 to conserve cash. OxiGene also will stop further enrollment in the Phase II/III FACT trial of Zybrestat fosbretabulin to treat advanced anaplastic thyroid cancer (ATC). The trial will continue to treat and follow the enrolled patients. OxiGene said the change will allow the company to analyze the data sooner, with a survival analysis expected in early 2011. The trial had an SPA from FDA and was originally scheduled to enroll 180 patients. The company expects that the SPA will no longer be applicable. Zybrestat is an A4 prodrug phosphatase-activated tumor vascular targeting agent. ...